Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects

Hye Duck Choi; Hye Jung Lee; Sang Hun Lee; Soo Hwan Kim; Chung Am Choi; Min Jung Chang; Wan Gyoon Shin

doi:10.5414/CP201671

Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects

Hye Duck Choi, Hye Jung Lee, Sang Hun Lee, Soo Hwan Kim, Chung Am Choi, Min Jung Chang, Wan Gyoon Shin

Department of Pharmacy

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t _1/2, and C _max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C _max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.

Original language	English
Pages (from-to)	345-348
Number of pages	4
Journal	International Journal of Clinical Pharmacology and Therapeutics
Volume	50
Issue number	5
DOIs	https://doi.org/10.5414/CP201671
Publication status	Published - 2012 May

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

Access to Document

10.5414/CP201671

Cite this

@article{51f4bfb97aa347aead081a19a32f54bf,

title = "Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects",

abstract = "Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t 1/2, and C max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.",

author = "Choi, {Hye Duck} and Lee, {Hye Jung} and Lee, {Sang Hun} and Kim, {Soo Hwan} and Choi, {Chung Am} and Chang, {Min Jung} and Shin, {Wan Gyoon}",

year = "2012",

month = may,

doi = "10.5414/CP201671",

language = "English",

volume = "50",

pages = "345--348",

journal = "International Journal of Clinical Pharmacology and Therapeutics",

issn = "0946-1965",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "5",

}

TY - JOUR

T1 - Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects

AU - Choi, Hye Duck

AU - Lee, Hye Jung

AU - Lee, Sang Hun

AU - Kim, Soo Hwan

AU - Choi, Chung Am

AU - Chang, Min Jung

AU - Shin, Wan Gyoon

PY - 2012/5

Y1 - 2012/5

N2 - Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t 1/2, and C max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.

AB - Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t 1/2, and C max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.

UR - http://www.scopus.com/inward/record.url?scp=84860760003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860760003&partnerID=8YFLogxK

U2 - 10.5414/CP201671

DO - 10.5414/CP201671

M3 - Article

C2 - 22541839

AN - SCOPUS:84860760003

SN - 0946-1965

VL - 50

SP - 345

EP - 348

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

IS - 5

ER -

Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this